12 Health Care Stocks Moving In Thursday's After-Market Session
I-Mab Publishes First-in-Human Data For Givastomig Monotherapy In 'Clinical Cancer Research', Showing Up To 18% Response Rate In Heavily Pretreated Gastric Cancer Patients; Safety And Efficacy Support Ongoing 1L Combination Trials With Nivolumab And...
IN8bio Regains Nasdaq Compliance With Bid Price Rule
Top Premarket Decliners
IN8bio Announces Patient 009 In Phase 1 Trial Of INB-200 For Newly-Diagnosed GBM Reaches Significant Clinical Milestone
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated With INB-200 in Glioblastoma Trial
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
In8bio To Carry Out 1-for-30 Reverse Stock Split On June 6th, 2025
June 4th (Eastern Time) - $In8bio(INAB.US)$ is about to implement a 1-for-30 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from June 6th, 2025.$In8bio(INAB.
IN8bio Shares Are Trading Lower After the Company Announced a 1-for-30 Reverse Stock Split.
Express News | IN8bio Inc - Reverse Stock Split Effective June 5, 2025 - SEC Filing
Express News | IN8bio Inc - on June 3, Files Certificate of Amendment for 1-for-30 Reverse Stock Split - SEC Filing
IN8bio's Promising Clinical Trial Results and Strategic Developments Justify Buy Rating
IN8bio Announces Positive Phase 1 Trial Results
Express News | IN8bio Inc - Inb-200 Is Well-Tolerated, Shows No Serious Toxicities Beyond Chemotherapy
Express News | IN8bio Presents Positive Phase 1 Data of Inb-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
IN8bio Shares Are Trading Lower. The Company Announced New Preclinical Data From Its INB-619 Program at the 2025 American Society of Gene & Cell Therapy Annual Meeting
12 Health Care Stocks Moving In Thursday's Pre-Market Session
IN8bio Presents Preclinical Data From INB-619 Program